



CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.

CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. With over 20 years of leadership in 4 areas of transplant innovation, our understanding of transplant patients and care teams allows us to develop solutions to extend graft life. With two decades of commitment to transplant care, we have developed close partnerships across the transplant ecosystem that grow stronger every day. CareDx is a global, 100% transplant focused company, demonstrating leadership in serving laboratories, researchers, and clinicians with its state-of-the-art product portfolio of next-generation sequencing (NGS) based AlloSeq products, which serve as pre- and post-transplantation solutions. For pre-transplant application, CareDx offers HLA typing solutions QTYPE and AlloSeq Tx. For post-transplantation monitoring, CareDx offers AlloSeq HCT chimerism testing and AlloSeq cfDNA for labs to measure the relative amount of donor derived cfDNA (dd-cfDNA) in solid organ transplant recipients. All products are CE marked or for Research Use Only (RUO) according to local regulatory requirements. CareDx also provides AlloSeq Tx and AlloSeq cfDNA testing services accredited to ISO 17025 for customers who prefer to use the CareDx service lab in Stockholm, Sweden.

Learn more about CareDx transplant lab products:

<https://caredx.com/products-and-services/transplant-lab-products/>